



6th April, 2026

To,
The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Certificate from CFO Pursuant Point no. 10 of Chapter XVII of SEBI Master Circular no. SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15th October, 2025

Ref: Commercial Papers issued under ISIN INE685A14187

Pursuant to SEBI Circular referred above, this is to inform you that the proceeds of Commercial Papers (CPs) issued by the Company under INE685A14187 have been fully utilized during the quarter 31st March, 2026 as per the purpose disclosed in the Disclosure Document and other listing conditions were adhered to as required under the aforesaid SEBI Circular.

Kindly take note of the above.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

SUDHIR MENON
EXECUTIVE DIRECTOR (FINANCE) & CFO

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059

Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

Email – investorservices@torrentpharma.com